Hypogonadotropic hypogonadal men respond less well to androgen substitution treatment than hypergonadotropic hypogonadal men.
This research asked whether androgen substitution therapy is as efficacious in hypogonadotropic hypogonadal men as in hypergonadotropic hypogonadal men. Erotosexual functions of two groups of six men of each diagnostic category were compared after 5-6 years of continuous androgen treatment. Treatment regimen was the same in both groups: Parenteral testosterone esters 250 mg/2 weeks. No difference was found in erectile and ejaculatory potency, but the number of sexual acts and scores of subjective quality of sexual acts, sexual excitement, and frequency of sexual thoughts and of nonsexual parameters as vigor, fatigue, anxiety were more negative in the hypogonadotropic men. The most obvious difference between the two groups is the value of LH/FSH and presumably of LHRH. Hypogonadotropic hypogonadal men may be better treated with gonadotropins (or with pulsatile LHRH, when the hypophysis is intact) than with androgens.
D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects; D000728:Androgens / Q000627:therapeutic use*; D004542:Ejaculation / Q000187:drug effects; D007987:Gonadotropin-Releasing Hormone / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D010410:Penile Erection / Q000187:drug effects; D012725:Sexual Behavior / Q000187:drug effects*
D000728:Androgens; D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone